Skip to content

Study on the diagnosis and intervention of attention deficit hyperactivity disorder

Study on the diagnosis and intervention of attention deficit hyperactivity disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057306
Enrollment
Unknown
Registered
2022-03-07
Start date
2021-06-15
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

Digital Treatment Group:Digital Treatment
Digital Treatment Placebo Group:Digital Treatment Placebo

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 6-12 years old , gender is not limited; (2) First-onset patients diagnosed by the attending physician and above of the Children's Health and Mental Health Center who meet the ADHD diagnosis in DSM-IV; (3) ) Normal IQ (Chinese Webster's Wisdom Scale for Children (C-WISC) evaluates IQ = 80), able to understand and perform tasks required for participating in research

Exclusion criteria

Exclusion criteria: 1. There are serious medical diseases such as heart, liver, kidney, glaucoma, secretion, etc.; or neuropsychiatric diseases such as epilepsy and mental retardation; 2. Diagnosed as tic disorder; 3. Abnormal auxiliary examinations and laboratory examinations deemed by the investigator to be clinically significant; 4. Participated in other drug clinical trials within 3 months before being selected; 5. Past history of game addiction; 6. Receive systematic psychotherapy at the same time; 7. Used monoamine oxidase inhibitors (MAOI), antipsychotics, antidepressants, and mood stabilizers 2 weeks before enrollment; 8. Suffer from a physical disease that can significantly enhance the activity of the sympathetic system (such as nerve tumors that secrete catecholamines), or take sympathomimetic drugs every day (such as albuterol, inhaled aerosol, pseudopilocarpine); 9. The investigator believes that there are other comorbid diseases or the drugs being taken may interfere with the safe application of positive drugs; 10. At any stage of the research, it is necessary to take psychotropic drugs other than the experimental drugs, including health care products that the researcher believes to have central nervous system activity [such as melatonin (cerebral platinum)]; 11. The researcher believes that the subject and/or the subjects' parents or guardians cannot fully understand the research or follow the requirements of the research.

Design outcomes

Primary

MeasureTime frame
Cognitive ability;Neuropsychological test;

Countries

China

Contacts

Public ContactYang Binrang

Shenzhen Children's Hospital

ybinrang@126.com+86 18938691619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026